Ferrous Gluconate
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Ferrous Gluconate: From Iron Supplementation to Plummer-Vinson Syndrome
One-Sentence Summary
Ferrous gluconate is an iron salt, and its SAHPRA record does not state an approved indication. The TxGNN model predicts it may be useful for Plummer-Vinson syndrome, an iron-deficiency-related condition. No clinical trials or publications were found for this indication, so the support is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record (iron salt used for iron supplementation) |
| Predicted New Indication | Plummer-Vinson syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ferrous gluconate supplies elemental iron, and its role in correcting iron deficiency is well established.
Plummer-Vinson syndrome combines difficulty swallowing, oesophageal webs and iron-deficiency anaemia. Iron replacement is the accepted mainstay of care. The link between the drug and the disease is therefore biologically plausible, and it probably explains the very high TxGNN score.
This is arguably an on-label-type use of iron rather than true repurposing. The value of this candidate lies in confirming the use locally, not in discovering a new one. The other four predictions for this drug are weaker:
- Megaloblastic anaemia (B12- and folate-independent), oesophageal malformation and biotin metabolic disease have no clear iron mechanism. Their scores look like knowledge-graph artefacts.
- Vitamin deficiency disorder is indirect, because iron is a mineral, not a vitamin. Four small trials of iron supplementation exist, but none tests correction of a vitamin deficiency.
Clinical Trial Evidence
Currently no related clinical trials registered for Plummer-Vinson syndrome.
Literature Evidence
Currently no related literature available for Plummer-Vinson syndrome.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 52/24/0031 | Nutryelt | Infusion | Not stated in the record |
The only registration found is an injectable (infusion) product. Whether an oral ferrous gluconate product is registered in South Africa was not established from the data provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible, since iron replacement is standard care for Plummer-Vinson syndrome. However, there is no trial or literature evidence in the pack (L5), and the safety information needed for screening is missing. The one local registration is an infusion product with no stated indication.
To proceed, the following is needed:
- SAHPRA Professional Information (warnings, contraindications, approved indication) for the registered product
- Confirmation of which ferrous gluconate formulations, oral or injectable, are available in South Africa
- Indication-specific literature on iron therapy in Plummer-Vinson syndrome
- Mechanism of action data from DrugBank
- If the vitamin deficiency prediction is pursued, a narrower target such as iron-deficiency anaemia or iron-folate use in pregnancy
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.